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THE most important function of the immune system is todiscriminate between ‘self’ and ‘nonself.’ The self
needs to be protected, whereas the nonself must be de-
stroyed. In some pathological processes the recognition of
self is lost and the immune system starts to attack self, lead-
ing to a so-called “autoimmune disease.”
Currently, the distinction between self and nonself is con-
sidered to involve a series of complicated and multistage
interactions between various cells of the immune system.
There is currently accumulating evidence that some cases of
premature ovarian failure (POF)1 are due to a faulty recog-
nition of self in the ovary by the immune system.
POF or premature menopause is a syndrome clinically de-
fined by failure of the ovary before the age of 40 yr (1). POF is
a heterogeneous disorder with a multicausal pathogenesis, and
chromosomal (2–9), genetic (4, 10–12), enzymatic (13–14), iat-
rogenic (15–20), or infectious (21–22) aberrations may all form
the basis for the disappearance of ovarian follicles. These ab-
errations may influence the ovary at any stage of life, including
the prepubertal, pubertal, or reproductive stages (23).
This review will primarily focus on the accumulating evi-
dence of an abnormal self-recognition leading to ovarian au-
toimmunity in a proportion of patients with POF. This places
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1 The following abbreviations are used: Ag(p), antigen (peptide),
APC, antigen presenting cell; APGS, autoimmune polyglandular syn-
drome; BB, Bio Breeding; CD, cluster of differentiation; Cy-Ad-Abs,
adrenal cytoplasmic antibodies; D, diversity; DC, dendritic cell; DTH,
delayed type hypersensitivity; EPM1, Unverricht-Lundborg type of pro-
gressive epilepsy; HLA, human leukocyte antigen; IDDM, insulin de-
pendent diabetes mellitus; IFN, interferon; Ig, immunoglobulin; IIF,
indirect immunofluorescence; IL, interleukin; J, joining; MHC, Major
Histocompatibility Complex; MIF, migration inhibiting factor; NK, nat-
ural killer; NOD, Non Obese Diabetic; NU, athymic nude; OS, Obese
Strain chicken; POF, premature ovarian failure; PTK, protein kinase;
ROS, resistant ovary syndrome; SLE, systemic lupus erythematosis;
SmIg, surface membrane bound immunoglobulins; SSLP, single se-
quence length polymorphisms; St-C-Abs, steroid cell antibodies; TCR, T
cell receptor; Th, T helper; TNF, tumor necrosis factor; V, variable; ZP,
zona pellucida; 17-a-OH, 17-alpha-hydroxylase; 21-OH, 21-hydroxy-
lase.
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some cases of POF in the group of autoimmune diseases that
affect hormone-producing glands, the so-called “autoimmune
endocrinopathies,” such as thyroiditis, insulin-dependent dia-
betes mellitus (IDDM), and Addison’s disease.
II. Definition and Clinical Presentation of Premature
Ovarian Failure (POF)
Menopause (cessation of menses on the basis of ovarian
failure) is in principle a physiological event. Women in west-
ern countries experience menopause at an average age of 50
yr (24–26). The number of primordial follicles decreases with
age (27, 28), and the ultimate disappearance of primordial
follicles in the ovaries is held responsible for the cessation of
ovarian function in menopause. However, morphologically
normal oocytes can be found in postmenopausal ovaries
using electron microscopy (29), indicating that such disap-
pearance cannot be the sole factor playing a role in the de-
velopment of the menopausal state. It has, for instance, been
hypothesized that the remaining follicles in perimenopausal
women are less sensitive to high levels of gonadotropins (30).
POF was defined by de Moraes-Ruehsen and Jones in 1967
(1) as an unphysiological cessation of menses before the age
of 40 yr and after puberty (hence, in fact, secondary amen-
orrhea). Women with POF have a hypergonadotropic-hy-
poestrogenic hormone profile. By 1939, the endocrinological
profiles of the syndrome had been recognized on the basis of
elevated levels of urinary gonadotropins (31). The clinical
picture of POF was first described in detail in 1950 by Atria
(32). This author reported 20 young women under the age of
35 yr with secondary amenorrhea, hot flushes, infertility, and
an atrophic endometrium. In retrospect, these cases presum-
ably were cases of POF, although at that time confirmatory
gonadotropin assays were not routinely performed.
Patients with POF are mainly troubled by infertility due to
the cessation of ovarian function. They have a typical men-
strual history of normal age at menarche (33, 34) followed by
regular periods. The disease thereafter presents either with
oligomenorrhea or abrupt amenorrhea. Presently, amenor-
rhea due to POF is also seen after termination of oral con-
traception (35–37). A family history of POF is incidently
obtained (10–12, 37). Fifty percent of patients with POF ex-
perience vasomotor symptoms, such as hot flushes and
sweating boosts (37–39) due to the hypoestrogenic status.
Other troubling symptoms are atrophy of the vagina and the
urological tract, leading to vaginitis, dyspareunia, and cys-
titis.
The diagnosis of POF rests upon the clinical picture and
the demonstration of elevated gonadotropin levels. The level
of FSH is disproportionally higher than that of LH (40).
Serum levels of FSH greater than 40 IU/liter are the hallmark
of the diagnosis. Serum gonadotropin determinations should
be repeated at least two or three times to be certain of the
diagnosis because serum gonadotropin levels may wax and
wane (41–43). POF presents itself not as an all-or-none phe-
nomenon, and the precise timing of onset is often impossible
to determine. The disease may have a fluctuating course,
with high gonadotropin levels that later return to normal,
and a later regain of ovulatory functions and even pregnancy
(44–46). Nelson et al. (47) examined 65 POF patients by
weekly estradiol sampling and sonography. In 50% of the
cases, follicular activity could be demonstrated, and 16% of
cases regained ovulatory function. Follicle biopsies were car-
ried out in six patients, and these showed luteinized Graafian
follicles (47). Alper et al. (44). reported that 7.5% (six of 80)
patients were able to conceive after a diagnosis of POF.
The incidence of POF in a population under the age of 40 yr
is estimated to be 0.9% (48). The choice of 40 yr as the age that
separates premature from normal menopause is arbitrary. If
one were to define abnormality as those values less or greater
than 2 sd from the mean age of menopause (where 6 95% of
the observations of a normally distributed variable are found),
then the age of 43 would be the most appropriate lower age limit
for the natural cessation of menses.
Kinch et al. (49) were the first to identify two histopatho-
logical types of POF: the afollicular and the follicular form.
In the afollicular form, there is a total depletion of ovarian
follicles and hence a permanent loss of ovarian function. Such
total depletion of ovarian follicles is mainly due to gonadal
dysgenesis, mixed gonadoblastoma, and hermaphroditism
[reviewed by Coulam (23)]. Genetic and chromosomal ab-
normalities are one of the most well known causes of germ
cell maldevelopment and disappearance (2). Such an accel-
erated loss of oocytes is considered to be the cause of POF in
individuals with a 47,XXX and 45,XO and 45,X0 mosaicism
(2, 9). Lack of migration of sex cells or faulty differentiation
of the gonadal ridges lead to streak ovaries or, in some cases,
to POF, depending on the actual number of primordial fol-
licles that result.
In the follicular form, follicular structures are still pre-
served and hence a possibility of either spontaneous or in-
duced return of ovarian function exists. The follicular form
can be subdivided into: 1) oo¨phoritis (inflammation of fol-
licles); 2) ovaries with a few follicles present; and 3) ovaries
in which numerous primordial follicles are present [the so-
called resistant ovary syndrome (ROS)] (50).
Although the histological classification suggests a sharp
division between the follicular and afollicular forms, there is
evidence that some cases of POF that were originally of the
follicular type may progress to an afollicular stage. This is
particularly the case in blepharophimosis (51, 52), galac-
tosemia (53), and in the animal models of autoimmune oo¨-
phoritis (see below).
Recent research suggests that ovarian autoimmunity is a
possible cause of both afollicular and follicular forms of POF.
This review will list the arguments, pro and con, to such a
view. At first, however, a short introduction into the cells
involved in the immune response and immunological prin-
ciples of self- and non-self-recognition will be given. This
information will provide the background necessary to un-
derstanding these arguments.
III. Cells Involved in the Immune Response
A. Antigen presentation and antigen-presenting cells, in
particular dendritic cells
An immune response against nonself- and self-antigens is
initiated by presentation of the antigen in a suitable form to
108 HOEK, SCHOEMAKER, AND DREXHAGE Vol. 18, No. 1
 at Medical Library Erasmus MC on December 13, 2006 edrv.endojournals.orgDownloaded from 
T cells. Antigen can only be presented to T cells in the context
of molecules of the major histocompatibility complex (MHC)
(54). Hence, practically each nucleated cell of the body is able
to present antigen, first by virtue of a constitutive MHC class
I expression, and second by a de novo expression of MHC
class II molecules on the surface of the cell, induced by f.i.
interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a)
exposition (55). Macrophages, B cells, and particularly den-
dritic cells (DC) are, however, the most efficient (profession-
al) antigen-presenting cells (APC) due to a variety of factors,
among which are the constitutive expression of MHC class
II molecules, the expression of costimulatory and adhesion
molecules, and other characteristics such as motility (56).
The genes encoding for both MHC class I and II molecules
are members of the immunoglobulin supergene family.
These genes in the human species are arranged on chromo-
some 6 [reviewed by Weetman (57)]. MHC class I genes
encode for the human leukocyte antigens (HLA) A, B, and C.
MHC class II genes encode the HLA DP, DQ, and DR anti-
gens. The encoded HLA molecules are dimers and comprise
an a- and b-chain (Fig. 1). The a-chain of the MHC class I
molecules is encoded in the MHC genes; the b-chain is
termed b2-microglobulin and is encoded on a separate chro-
mosome.
The overall structures of the class I and II MHC molecules
are comparable (58). The molecular confirmation of the
chains forms a groove in which the antigenic peptide is
presented. Thus the ability of antigenic peptides to be asso-
ciated with class I or class II MHC molecules is governed by
the actual molecular confirmation (tertiary structure) of the
antigen-binding groove. It is therefore not surprising that
organisms with a particular genetic makeup of MHC class I
and II molecules have a special capacity to generate immune
responses toward specific microbial and self-antigens.
An additional molecule, known as the invariant chain, is
intimately involved in the biology of HLA class II molecules.
The invariant chain is a membrane glycoprotein, encoded by
a non-HLA gene on chromosome 5. The “invariant” desig-
nation stems from the observation that, in contrast to the
extensive polymorphism of some class II a- and all class II
b-chains, the invariant chain is nonpolymorphic. It forms a
trimer with the class II a- and b-chains in the endoplasmic
reticulum during biosynthesis of the MHC class II molecules
and directs the trafficking of the trimer through the post-
translational machinery of the cell to the endosomal com-
partment (Fig. 2). Current evidence indicates that the invari-
ant chain also prevents peptides from binding in the class II
groove until the class II molecule is delivered to the endo-
some. The invariant chain then dissociates from the class II
molecule, which can consequently bind antigenic peptides
processed from exogenous antigens taken up by the APC and
degraded in its lysosomal compartment (Fig. 2). The latter
fuses with endosomes (59–61). The complex of the class II
molecule with its bound peptide is then transported to the
cell membrane (Fig. 2); however, the mechanism of transport
FIG. 1. The structure of MHC-class I (A) and MHC-class II (B) mol-
ecules within the binding groove the antigenic peptides (Agp) [Re-
produced with permission from the authors from: Benner R, van
Dongen JJM, van Ewijk W, Haaijman J (eds) Medische Immunologie.
Bunge, Utrecht, The Netherlands, 1996].
FIG. 2. The processing of exogenous antigens to result in the posi-
tioning of antigenic peptides in the groove of the MCH-class II mol-
ecule [Reproduced with permission from the authors from: Benner R,
van Dongen JJM, van Ewijk W, Haaijman J (eds) Medische Immu-
nologie. Bunge, Utrecht, The Netherlands, 1996].
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is still unclear. Due to this intracellular pathway, exogenous
antigens are mainly presented in association with MHC class
II molecules (62). Peptides associated with MHC class II
molecules can only be presented to CD41 T cells (63), because
the CD4 molecule is a special receptor for the MHC class II
molecules (Fig. 3).
Endogenous antigens, e.g. viral antigens, are degraded by
the low molecular mass polypeptide complex present in the
cytoplasm (64). Peptides are then delivered to the MHC class
I molecules in the lumen of the endoplasmic reticulum. After
incorporation of the antigenic peptides into the groove and
exposure of the MHC class I molecules on the cell surface,
only CD81 T cells are able to recognize such peptides, be-
cause the CD8 molecule is the special receptor for MHC class
I molecules (Fig. 3). After recognition, CD81 T cells are able
to kill the cell presenting the endogenous antigen (54, 65).
Neither class I nor class II MHC molecules can distinguish
between self and nonself (66, 67). It must also be noted that
the preferential association of exogenous antigens with MHC
class II molecules, and endogenous antigens with MHC class
I, is not absolute (62, 68).
The complex of MHC molecule-antigenic peptide-T cell
receptor (TCR) is insufficient for an adequate activation of
the T cell. For full activation, the interaction of other acces-
sory molecules on APC with their ligands on T cells is
needed, such as the interaction of adhesion molecules (69–
71). The binding produced by these adhesion molecules pre-
dominantly strengthens the interaction between the MHC-
antigenic peptide-TCR interaction, but also transduces
signals that activate the T cell. Important adhesion molecules
are leukocyte function antigen 1 (LFA-1), which interacts
with intercellular adhesion molecule 1 (ICAM-1), and leu-
kocyte function antigen 3 (LFA-3), which interacts with CD2
(70, 71) (Fig. 3). Inhibition in this process by monoclonal
antibodies to either one of these adhesion molecules inhibits
the activation and clonal expansion of T cells (69).
Apart from the adhesion molecule-ligand interaction, the
interaction of so-called “costimulatory molecules” on APCs
and T cells is essential for further T cell activation and T cell
clonal expansion (Fig. 3). If these costimulatory signals are
not provided, the result is T cell anergy [a state of specific
nonresponsiveness of T cells (72)]. Costimulating signals are
predominantly provided by the binding of the B7-1 (CD80)
molecule on the APC (73, 74) to the CD28 molecule on the T
cell. Additional binding of T-lymphocytic CTLA-4 (cytolytic
T lymphocyte-associated antigen) to B7-2 (CD86) molecules
on the APC also takes place but it occurs probably later in the
process, because CTLA-4 is primarily seen on the T cells after
activation (75).
DCs are unique APCs in that they are the only APCs that
are able to effectively stimulate naive (CD45RA1) T cells
(76–78). Recent investigations led to the idea that the DC
population is heterogeneous with respect to ontogeny (79).
It is certainly heterogeneous with respect to morphology, the
expression of adhesion molecules (80–83), and in cytokine
production. With regard to ontogeny, part of the DC pop-
ulations is monocyte-derived and closely associated with
macrophages, whereas other DCs may have a separate pre-
cursor [this subject was extensively reviewed by Kamperdijk
et al. (84)]. DCs are found in virtually all tissues and organs
of the body. The DC of the epidermis and dermis is known
as the Langerhans cell. Langerhans cells contain the peculiar
Birbeck granules that are not seen in DC in other organs,
apart from the thymus. Langerhans cells of the skin and DC
of the gut wall are considered as early (immature) stages in
the differentiation of the cell, with a superb capacity to pick
up antigens and to degrade these to antigenic peptides and
place these peptides in the groove of the MHC molecules.
Skin Langerhans cells and gut DCs have been shown to
migrate into the afferent lymph as veiled cells to the skin- and
gut-draining lymph nodes (Fig. 4). These cells can be seen as
interdigitating cells in the T cell areas of these draining
lymph nodes, and these stages of the DC are considered as
mature stages of the cell with a superb capacity to stimulate
T cells (85). It seems likely that DC from other organs, like the
heart, kidney, and endocrine organs, may undergo similar
migration and maturation.
Whereas macrophages are a clear source of cytokines such
as interleukin-1 (IL-1), IL-6, and TNF-a, DC have been shown
to produce the mRNAs of these cytokines, without a note-
worthy production of the actual products (84, 86, 87). In
general, DCs are regarded as poor producers of cytokines,
and their excellent APC function lies probably in their mi-
FIG. 3. The interactions between APC (including virus- infected cells)
and T cells at the level of antigen-specific interactions, adhesion
molecules, and costimulatory molecules. Panels A and B represent
interactions between MHC molecules, the TCR, and CD4/CD8 mol-
ecules. Panel C depicts interactions between various adhesion mol-
ecules (ICAM-1/LFA1, LFA-3/LFA-2, CD45/unknown) providing sig-
nal 1 for T cell stimulation, and interactions of the costimulatory
molecule CD80(B-7)/CD28, providing second signals (for abbrevia-
tions see Table 1).
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gratory capacity, their capability to form clusters with T cells
via adhesion molecules (88, 89), and their high expression of
costimulatory molecules such as B7-1 and B7-2 (CD80/CD86)
(90).
It is as yet unresolved whether the DC needs other cyto-
kine-producing accessory cells to guide the generated clonal
expansion of naive T cells in a certain direction of develop-
ment. IL-12 is known to be produced by macrophages, and
this cytokine is able to push the development of T cells into
T cells that predominantly produce IFN-g (91); however,
IL-10 (also produced by macrophages) down-regulates such
development (92, 93).
B. T cells
The ability of the immune system to specifically recognize
all varieties of possible antigens is based on the enormous
diversity of the antigen-specific receptors present on the T
cells (TCR) and the enormous diversity of the surface mem-
brane-bound immunoglobulins (smIg-receptors) on the B
cell (94–97). When the TCR fits with the antigenic peptide in
the groove of the MHC molecule, lymphocyte activation and
clonal expansion will be initiated (95–97) provided the suf-
ficient adhesion molecule and costimulating signals are
given. A specific TCR can bind only one form of an antigenic
peptide, and this will consequently lead to cell division of
this type of TCR-specific lymphocytes. This is referred to as
clonal expansion.
The TCR is composed in the majority of cases of an a- and
b-chain (96–98) or in a minority of cases of a g- and d-chain
(99–102). The various chains of the TCR are encoded by
different gene segments: variable (V), diversity (D), joining
(J), and constant (C) gene segments. The V, D, and J gene
segments form a large repertoire. The enormous diversity of
the TCR is produced by the recombination of the various V,
D, and J genes from this large repertoire during T cell mat-
uration (103,104). Thus, the capacity to react with all possible
antigenic peptides is genetically programmed and created by
germ line rearrangements and somatic mutations. The TCR
is noncovalently linked to a series of transmembrane proteins
called the CD3 complex (Fig. 3) (98, 102, 105, 106). Both CD4
and CD8 molecules on the T cells act as coreceptors for the
MHC class II and MHC class I molecules, respectively, dur-
ing the interaction of the TCR with the peptide-MHC com-
plex (107, 108). The entire CD3/TCR/MHC-II/CD4 complex
or the entire CD3/TCR/MHC-I/CD8 complex is involved in
signal transduction (Fig. 3).
The identification and classification of various T cells (Ta-
ble 1) is based on the expression of the CD3 complex, the
coexpression of either CD4 or CD8 molecules, and the com-
position of the TCR (genetic makeup of various V, D, and J
genes).
Over the past few years it has become clear that the pop-
ulation of CD41 T cells can functionally be divided into two
subsets based on their profile of cytokine production (109,
110) (Fig. 5). One subset predominantly produces IFN-g, but
also IL-2; this is the so-called Th1 subset. The other subset,
Th2, produces predominantly IL-4 and IL-5. The functional
significance of these different cytokine production profiles is
that they represent different T cell-regulatory actions. Th1
cells and their cytokine products stimulate macrophages and
hence cell-mediated immunity and macrophage-mediated
cellular destruction. Th2 cells and their cytokine products
stimulate B cells and hence lead to the humoral immune
response. It must be noted, however, that the Th1 and Th2
subtypes represent extremes. There are many CD41 T cells
clones with a cytokine production profile intermediate be-
tween Th1 and Th2 cells. The driving of CD41 T cells (Tho
cells, Fig. 5) into either the direction of Th1 or Th2 is guided
in a complicated network by the cytokines IL-1, IL-12, IL-10,
IFN-g, IL-4, and products of arachidonic acid metabolism
(91–93, 111–115).
C. B cells
B cells are generally identified by means of the expression
of SmIg-receptors on their cell surface or by the expression
of B cell-specific molecules (Table 1). When the SmIg-recep-
tor of a B cell recognizes the antigen against which it is
directed, and when sufficient additional stimulatory signals
are provided (see below), proliferation will occur. The gen-
erated B cells will thereafter differentiate into plasma cells
that start to secrete immunoglobulins with a specificity sim-
ilar to that of the earlier membrane-bound form of immu-
noglobulin.
When antigen-specific B cells and activated T cells recog-
nize the same antigen or a peptide thereof, a so-called “cog-
nate interaction” occurs (Fig. 6). The B cell uses its SmIg
receptor for uptake and concentration of the antigen (116).
The antigen is processed and the antigenic peptides are pre-
sented on the B cell surface in the groove of the MHC class
II molecules to the antigen-specific T cell. When the cognate
interaction activates the T cell to produce and release the
cytokines IL-4 and IL-5 (Th2 pathway), the B cell is stimu-
FIG. 4. A scanning electron microscopy photograph of a DC in lymph
in contact with a lymphocyte (50003)(pig).
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lated to clonally expand and differentiate into a plasma cell
to produce specific antibodies (117).
SmIg receptors on B cells show, like the TCR, a specificity
toward antigens that is already programmed and created by
germline gene rearrangement and somatic mutations
(103,104). An enormous variety of antibodies can thus be
produced. Antibodies are composed of two Ig heavy chains
and two Ig light chains held together by disulfide bonds
(118). Antibodies play an important role in the neutralization
of bacterial toxins and in the opsonization of microorganisms
for phagocytosis.
Antibodies are produced in different isotypes (IgA, IgG,
IgM, IgE, IgD). The isotype is important in determining
whether an antibody will fix complement (118). The majority
of B cells in the peripheral blood express IgM and IgD on
their cell surface, whereas a few express IgG or IgA. Secreted
IgM antibodies are of low affinity and polyspecific. Secreted
IgG and IgA antibodies are of high affinity and high spec-
ificity and are typical of secondary immune responses. The
TABLE 1. CD markers, respectively, for T cells, B cells, monocytes/macrophages, dendritic cells and NK cells
CD Name Function
T cells
CD2 T11 antigen; LFA-2 Receptor for T cell activation; ligand for LFA-3
CD3 T3 antigen Associated with TCR; signal transduction from TCR to cytoplasm
CD4 T4 antigen Involved in MHC-class II restricted antigen recognition
CD8 T8 antigen Involved in MHC-class I restricted antigen recognition
CD11a LFA-1 antigen Adhesion molecule binds to ICAM-1 and ICAM-2
CD25 Tac antigen IL-2 receptor/activation T cells (B cells and macrophages)
CD28 Tp44 antigen Receptor for B7/BB-1 antigen on activated B cells/T cells
proliferation
CD45 LCA; T200 antigen Function unknown, common leukocyte antigen
CD45RO Restricted LCA Activated (memory) T cells
CD45RA Restricted LCA Virgin T cells, monocytes
B cells
CD5 T1 antigen Function in T cell proliferation, unknown function in B cells
CD19 Pan-B cell antigen Function in B cell activation
CD20 B cell antigen Function in B cell activation
CD22 B cell antigen Function in B cell adhesion and activation
SmIg Surface membrane
immunoglobulin
Binding molecule for antigens
Monocytes/macrophages
CD11b,c Adhesion molecule on
monocytes/macrophages
MAC-1 antigen, p150-95 antigen; associated with CD18
antigen/adhesion molecule
CD14 Monocytic antigen LPS receptor
CD68 Macrophage antigen Function unknown
Dendritic cells
CD1 T6 antigen MHC-like protein (antigen-presentation)
CD83 HB15 molecule Function unknown
S100 Intracellular growth factor
NK cells
CD16 FcgR111 Low affinity Fc receptor for IgG (also present on macrophages)
CD56 NCAM Function unknown
CD57 Human natural killer
cell antigen
Function unknown
CD, Cluster of differentiation; CR, complement receptor; ICAM, intercellular adhesion molecule; IgG, immunoglobulin G; LCA, leukocyte
common antigen; LFA, leukocyte function antigen; LPS, lipopolysaccharide; MHC, major histocompatibility complex; NCAM, neural adhesion
molecule; TCR, T cell receptor. [Derived from Ref. 176.]
FIG. 5. The dichotomy in the action of CD41 T cells in the Th1 and
Th2 pathway and the action of various cytokines in the skewing of
these pathways (1, activation; –, suppression).
FIG. 6. The cognate interaction between Th2 cells and B cells to
result in the specific stimulation of antigen-specific B cells. [Repro-
duced with permission from the authors from: Benner R, van Dongen
JJM, van Ewijk W, Haaijman J (eds) Medische Immunologie. Bunge,
Utrecht, The Netherlands, 1996.]
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switch in immunoglobulin heavy chains from IgM and IgD
to IgG or IgA is referred to as the isotype switch (119). This
isotype switch is mediated by gene rearrangement in which
the V region is coupled to another C region (119, 120). Au-
toantibodies of the IgG isotype are characteristic of certain
pathological autoimmune reactions. To induce such antibod-
ies, the help of autoantigen-specific Th2 cells is a prerequisite.
D. Effector cells in immune responses
Effector cells in immune responses are macrophages, nat-
ural killer (NK) cells, and cytotoxic CD81 T cells. Macro-
phages form a heterogeneous population. Apart from im-
mune regulation, certain subsets of macrophages act as
important scavenging cells. They are able to endocytose and
phagocytose microorganisms and cellular debris (121), as
well as exerting cytotoxicity against microorganisms or tu-
mor cells (122). The main function of macrophages is con-
sidered to be phagocytosis. Phagocytosis of microorganisms
and cellular debris is greatly enhanced by opsonization of the
material by specific antibodies, as well as the capability of the
Th1 cytokine IFN-g to strongly activate the cytotoxic prop-
erties of macrophages, increasing their efficiency in killing
the microorganism (123). Macrophages also play a role in
wound healing (124, 125) and in the regulation of hemo- and
lymphopoiesis (126, 127). Histologically classic macrophages
are large cells that show lamellapodia and vacuoles and
possess an irregular, indented nucleus (128). They stain for
nonspecific esterase and acid phosphatase throughout the
cytoplasm.
Though precursors of macrophages certainly reside in the
monocyte pool the origin of all macrophages is not com-
pletely elucidated. A separate precursor in the bone marrow
may exist for some subpopulations of macrophages (128).
The monoblast and promonocyte remain in the bone marrow
very briefly before entering the blood stream as monocytes
(129). These latter cells migrate into the tissues where part of
the cells mature and differentiate into various lines of mac-
rophages such as the Kupffer cells, the osteoclasts, and the
histiocytes. There is not one monoclonal antibody that rec-
ognizes all the lines and maturation stages of macrophages
and that does not show a cross-reactivity with other hema-
topoietic cells. The lack of a common marker for all the
subpopulations of macrophages is inherent to their func-
tional heterogeneity. In human studies, macrophages are
normally identified by specific CD markers (Table 1).
In exerting their various functions, macrophages are able
to produce a variety of signaling molecules, such as the
cytokines IL-1, IL-6, granulocyte-macrophage-colony-stim-
ulating factor (GM-CSF), and TNF-a (128). Metabolites of
arachidonic acid metabolism, nitric oxide and oxygen radi-
cals, are also important products for the regulation of the
immune response and the degradation of ingested material.
NK cells and CD81 cytotoxic T cells are other important
immune cells in the effector arm of the immune system. NK
cells do not express conventional antigen receptors, such as
the TCR or SmIg-receptors, and the genes for these receptors
remain unrearranged (130, 131). They do express the receptor
for the Fc part of the IgG molecule, the FcgRIII (CD16) (132,
133). Other important molecules expressed by NK cells in-
clude CD56, a neural adhesion antigen, and the b-chain of the
IL-2 receptor. This allows resting NK cells to respond directly
to IL-2 (134). The main function of NK cells is to provide
nonspecific cytotoxic activity toward virally infected cells
and tumor cells (135, 136). They do so by releasing perforin
(pore forming) and serine proteases (137). NK cells, like
macrophages, can also kill specifically if provided with an
antibody. The process, known as antibody-dependent cellu-
lar cytotoxicity, occurs via binding of the antibody to the Fc
receptor (CD16). The ontogeny of NK cells is only partially
understood. Although NK cells express a number of mem-
brane antigens in common with T cells and share functional
properties with some T cell subsets, suggesting a common
origin, NK cells are found in the fetus before the develop-
ment of T cells or of the thymus. In addition, NK cells appear
to develop normally in nude, athymic mice (135). Recent
studies have indicated that NK cells can arise from triple
negative (CD32/CD42/CD82) thymocyte precursors that
are CD561 but do not express CD34 or CD5 (138). It must also
be noted that NK cells are not only considered as effector cells
in the immune response, but also as regulator cells. They are
sensitive to activation by Il-12, produce g-IFN that activates
the TH1 response, and are polyclonal activators of B cells
(139).
Cytotoxic T lymphocytes consist of mature T cells that are
usually, but not always, CD81. They exert cell contact-de-
pendent cytotoxic functions through a perforin-dependent
pathway (140). The cells also release the cytotoxic cytokine
TNF. The perforin-dependent pathway is largely responsible
for the T cell-dependent cytotoxic clearance of virus-infected
cells and for rejection of tissue grafts and tumors (141).
IV. Tolerance to Self
The main function of the immune system is to distinguish
between self and nonself. In healthy individuals, reactivity
toward self is nowadays considered to be a normal event that
is controlled by several down-regulating mechanisms. Mal-
function of these down-regulating mechanisms may result in
an undesired excessive immune reaction toward self, i.e. an
autoimmune disease. Among the best studied controlling
mechanisms are the following: clonal deletion in the thymus,
clonal anergy, and active immunosuppression by self-reac-
tive subsets of T and B cells (142).
A. Clonal deletion
T cells mature in the thymus from prothymocytes to ma-
ture T cells. Because TCR rearrangement is random, self-
reactive T cells are generated in this process. However, the
vast majority of self-reactive T cells are deleted during fur-
ther maturation in the thymus, the so-called “clonal deletion”
(143, 144). DCs occurring in great numbers at the cortico-
medullary junction of the thymus express self-antigens and
are responsible for this deletion. Clonal deletion depends
upon recognition of the self-antigenic peptides by not fully
matured T cells, which, upon the antigenic recognition sig-
nal, do not proliferate but go into apoptosis (145). A similar
mechanism of deletion may exist for self-reactive B cells in
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the bone marrow (146). This mechanism is, however, not so
well studied as clonal T cell deletion in the thymus.
Clonal deletion for T and B cells is, however, incomplete,
and T and B cells with a specificity for autoantigenic peptides
and autoantigens can easily be found in the circulation (147).
This is partly explained by the fact that not all self-antigens
are expressed in the thymus and bone marrow. Some self-
antigens, such as ocular lens antigens, are sequestrated from
the immune system. Other self-antigens, such as sperm-an-
tigens, are only expressed during late fetal life or only in
adult life. Some autoantigens probably never reach the thy-
mus or bone marrow and are never expressed there. This
particularly applies to cryptic epitopes. Cryptic epitopes are
de novo expressed epitopes on self-antigens that are caused
by changes in the antigen after, for instance, an inflammatory
process.
B. Clonal anergy
When autoreactive B and T cells have escaped clonal de-
letion, a second control mechanism, namely the process of
clonal anergy, should come into operation. This process takes
place predominantly in the periphery (148–150). The induc-
tion of an immunologically anergic state of the T cell is
supposed to be due to a lack of provision of sufficient second
signals by APCs. Hence, when antigen is presented to T cells
by nonprofessional APC, such as MHC class II-positive ep-
ithelial cells, clonal anergy will occur. Late in organ-specific
autoimmune diseases (e.g. in autoimmune thyroiditis and
IDDM) there is an aberrant expression of MHC class II mol-
ecules on the epithelial cells of the endocrine tissues (151).
Initially, this aberrant expression of MHC class II molecules
was interpreted as an impetus for the increased self-reactiv-
ity (152). However, this aberrant MHC class II expression late
in organ-specific autoimmune disease can also be considered
as a sign of induction of clonal anergy (151, 153).
C. Active immunosuppression
When clonal deletion and clonal anergy have failed, yet
another down-regulating mechanism should come into op-
eration, namely active immunosuppression exerted by so-
called “suppressor” immune cells. These suppressor im-
mune cells do not only include CD41 and CD81 T cells (154,
155), but also suppressor macrophages. The cells involved in
immune suppression may be antigen-specific or non-anti-
gen-specific. They may also operate in an idiotype-antiidio-
type network (155). How active immune suppression is reg-
ulated remains unclear. Taken together, earlier and recent
evidence suggests that in each individual a balance exists
between autoreactive effector and suppressor immune cells.
In the healthy state this balance tips over in favor of the
suppressor forces, whereas in the autoimmune diseased state
the balance is in favor of the self-reactive effector forces (see
also later animal models of autoimmune oo¨phoritis).
D. Balance between Th1 and Th2 pathways
A recently developed theory approaches the problem of
the control of self-reactivity from yet another angle. Endo-
crine autoimmune diseases with an ultimate failure of the
target gland, such as IDDM, are predominantly caused by
Th1-mediated pathways in which the endocrine cells are
destroyed by g-IFN-activated scavenger macrophages. The
recently developed theory emphasizes the reciprocal relation
between the Th1 and Th2 pathways (109, 156) and suggests
that if the Th1 pathway is diverted into the Th2 pathway that
the Th1-mediated autoimmune reactivity is dampened. In
essence, tolerance to self is not restored, but the harmful
autoimmune reaction is diverted to a less harmful one. There
are indeed reports on cytokine treatments that are able to
induce such a switch from Th1 to Th2 pathways, resulting in
an amelioration of the endocrine autoimmune disease. Cir-
culating antibodies, whose production is switched on by the
stimulation of the Th2 cells, apparently contribute little to the
damage of the target cells. It is known that endocrine auto-
antibodies may exist for years in the circulation before en-
docrine autoimmune disease develops (157, 158).
V. Autoimmune Endocrine Disease: Developmental
Stages and Genetic Predisposition
Before presenting the pros and cons for considering POF
as a possible endocrine autoimmune disease, it must be noted
that there are similar failures of endocrine organs that are
currently classified as autoimmune destructive diseases.
These endocrine failures include hypothyroidism (thyroid
failure), IDDM (failure of the islets of Langerhans), and Ad-
dison’s disease (failure of the adrenal cortex). The patho-
genesis of the failure of these endocrine tissues has mainly
been studied in animal models of the spontaneous forms of
these autoimmune endocrinopathies. The obvious reason for
this approach is that in the patients, tissues, cells, and sera are
difficult to obtain and only then in the progressed stages of
the disease.
The animal models for autoimmune disease of the thyroid
are the Obese Strain of chicken (OS chicken) (159), the Bio
Breeding (BB) rat (160), and certain strains of the Non Obese
Diabetic (NOD) mouse. The BB rat and NOD mouse also
suffer from an autoimmune insulitis leading to IDDM. An-
imal models for spontaneous autoimmune adrenalitis and
oo¨phoritis are lacking. Only manipulations of normal mice
(immunization with crude adrenal and ovarian extracts, and
thymectomy plus cyclosporin A treatment) will lead to au-
toimmune adrenalitis and/or oo¨phoritis (161). A word of
caution is necessary when trying to extrapolate data obtained
in the animal models to the human situation: the animal
models clearly show exaggerated and extreme forms of thy-
roiditis and insulitis, which already differ between the mod-
els themselves (let alone from patients), indicating a heter-
ogeneity of the disease process. Hence, general conclusions
drawn on the basis of studies in one animal model should
always be verified in other animal models and certainly in
human patients.
The animal models of insulitis and thyroiditis indicate that
the pathogenesis of the autoimmune failure of an endocrine
gland is a multistep process, requiring several genetic and
environmental abnormalities to come together before full-
blown autoimmune thyroiditis and/or insulitis develops.
The following phases in the disease process can be discerned
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(Fig. 7): 1) An initial phase of early accumulation of APC and
accessory cells (DCs, subclasses of macrophages) in the en-
docrine tissue; 2) A later phase of an apparently uncontrolled
production of autoreactive CD41 and CD81 T cells and of
autoantibodies of the IgG class in the draining lymph nodes;
3) A last phase where the target endocrine tissue becomes
susceptible for the autoimmune attack by the generated au-
toreactive T cells and autoantibodies; this finally results in
the destruction of the glandular tissue.
In the thyroids of patients with Graves’ disease or Hashi-
moto goiter, and in the thyroids and islets of the above
described animal models, increased numbers of specific sub-
sets of macrophages and MHC class II-positive DC have been
described (162). In the animal models, an increase in the
number of these cells in the future target glands and a local
clustering of these cells with T cells are the first signs of the
developing autoimmune reaction (151, 163). This local en-
hanced accumulation precedes the clonal expansion of T cells
and B cells in the draining lymph nodes, the production of
autoantibodies by these lymph nodes, and further signs and
symptoms of the later autoimmune disease. Foreign antigens
of viral or bacterial origin (164), or self-antigens altered by
toxins and drugs (165), or an excessive metabolic activity of
the endocrine tissue (166) have all been described as separate
possible causes of the attraction of the DCs to the endocrine
tissue, already indicating a heterogeneity in causal factors at
the level of the initiation of an endocrine autoimmune dis-
ease.
The initial phase of glandular accumulation of macro-
phages and APCs is followed by a phase of an apparently
uncontrolled clonal expansion of autoreactive T cells and B
cells and the production of autoantibodies in the draining
lymph nodes. In both the BB rat and the NOD mouse, there
are strong indications for a genetically linked systemic im-
munodysregulation leading to the local exaggerated produc-
tion of T cells, B cells, and IgG antibodies to various self-
antigens. This systemic immune abnormality is partly
associated with the presence of particular MHC class I and
class II haplotypes (see below) and apparently leads to ab-
normalities in the stimulation and differentiation of cells
involved in tolerance induction, such as the APCs, macro-
phages, and/or T cells (169). Indeed, APCs of NOD mice
(169) and BB rats (our unpublished observations) have de-
fects in their capability to generate T suppressor cells. With
regard to such abnormal maturation of immunoregulatory T
cells, the BB rat is special in that it lacks a regulator popu-
lation of T cells (the RT6 cells). BB rats also show a rapid
thymic involution (170). The OS strain of chickens has inborn
defects in its suppressor cell system (159). Whether there are
similar inborn defects in immunoregulatory cells in the hu-
man that lead to an endocrine autoimmune disease needs to
be established. There are, however, numerous reports on
both numerical and functional deficits in the suppressor cell
system of patients with thyroiditis and IDDM (171).
Deficits in immunoregulatory cells do not only exist on an
inheritable, genetic basis. They can also be acquired by (fetal)
viral infections. In chickens, Avian Leucosis Virus has
proven to exert a detrimental effect on thymus and bursa
development, which disturbs delicate immune regulatory
systems, leading to thyroid autoimmunity (172). Whether
similar viruses or retroviruses with an affinity for immune
cells are operative in human endocrine autoimmune diseases
has been speculated upon but has not yet been proven. Ex-
periments to detect virions and/or retroviral antigens have
not been conclusive in showing the involvement of infectious
viruses in human endocrine autoimmune disease (172).
After the stage of the excessive generation of autoreactive
T cells and IgG autoantibodies, yet another factor or factors,
at least in the OS chicken, determine whether or not a full
blown autoimmune disease will develop (173). A prerequi-
site for clinical thyroid failure in this bird is a susceptibility
of the target, the thyrocyte, for an autoimmune attack by the
generated autoreactive T cells and IgG autoantibodies. Ex-
periments have shown that this susceptibility factor is ge-
netically determined, and it has been speculated that this
factor might be an abnormal susceptibility of the thyrocytes
for the cytokines produced by the autoreactive immune cells
after infiltration. Whether such susceptibility factors are also
important in the other animal models and in human disease
needs further investigation, although in the BB rat a high
susceptibility of pancreatic islet cells for IL-1 has been es-
tablished.
Population, family, and twin studies have clearly shown
that genetic factors exert a significant influence on the pre-
disposition for an autoimmune endocrine disease. It is also
clear that environmental factors (diet, infections, etc) con-
tribute to disease expression because concordance rates in
monozygotic twins and inbred animals are often imperfect.
Since endocrine autoimmunity can be transferred by lym-
FIG. 7. The three developmental stages in an autoimmune endocrine
disease.
February, 1997 PREMATURE OVARIAN FAILURE AND OVARIAN AUTOIMMUNITY 115
 at Medical Library Erasmus MC on December 13, 2006 edrv.endojournals.orgDownloaded from 
phocytes and bone marrow precursor cells into recipients,
genes associated with the immune system have received
prime attention. At present, convincing evidence does not
exist for a relationship between the predisposition to an
endocrine autoimmune disease and particular TCR haplo-
types or polymorphisms, immunoglobulin allotypes and id-
iotypes, or cytokine genes (174). However, there is a clearly
established genetic association with genes encoding for the
MHC. In the BB rat this is the Rt1 haplotype (167), and in the
NOD mouse the H2 g7 haplotype (168). The human thyroid,
islet, and adrenal autoimmune diseases are predominantly
associated with HLA-DR3, DR4, and DR5 haplotypes (57).
The MHC may affect predisposition to endocrine autoim-
mune disease by several mechanisms that are not mutually
exclusive. Autoantigenic peptides of glandular autoantigens
may combine more easily with these particular MHC mol-
ecules than with others. It is, however, also possible that the
disease association with these MHC haplotypes is due to a
specific MHC-controlled shaping of the T cell repertoire.
Regardless of the mechanisms, it is apparent that the MHC
haplotype per se is insufficient for the development of an
endocrine autoimmune disease, as shown by the fact that
autoimmunity-associated HLA-DR haplotypes are also
found in perfectly normal individuals. Also, the H2 g7 hap-
lotype of NOD mice in congenic strains does not lead to
IDDM in these animals. The genetic analysis of endocrine
autoimmune diseases evidently requires an approach other
than detailed typing of the MHC encoding genes. Such an
approach has been found in the study on microsatellites.
Microsatellites or single-sequence length polymorphisms
(SSLPs) are repeat sequences [usually dinucleotides, e.g.
(CA)n] that exhibit high degrees of polymorphism both be-
tween individuals and in the number of repeats at a given
chromosomal site. SSLPs are abundant (.100.000) and are
randomly dispersed throughout the mammalian genome,
thereby providing an enormous pool from which to derive
markers (175). Several thousand microsatellite markers have
thus far been identified and mapped to the mouse/rat and
human genomes, respectively. Specific SSLP loci can easily
be defined by PCR using oligonucleotide primers specific for
conserved sequences flanking the individual repeats, and
length polymorphisms among individuals are identified by
electrophoresis of the amplified products on agarose or poly-
acrylamide gels. Todd et al. (168) pioneered the use of mic-
rosatellites and other informative markers to define broadly
the genes associated with diabetes in NOD mice. Scanning
the entire genome of the NOD mouse, they obtained evi-
dence of linkage with ten distinct loci, termed Idd-1 to -10,
distributed on at least nine different chromosomes and af-
fecting different immunopathological features (Table 2).
With the exception of Idd-1, which is linked with the MHC
locus on chromosome 17, no individual locus appears to be
absolutely essential for disease onset.
In addition to susceptibility loci, microsatellite mapping
studies in F2 crosses between NOD and a diabetes-free strain,
as well as between NOD congenic strains expressing normal
background alleles at specific Idd loci, have permitted the
identification of several protective alleles that confer various
degrees of resistance to diabetes. It can be predicted that
similar diabetes resistance genes exist in diabetes-free hu-
mans with diabetogenic MHC haplotypes.
In human IDDM, previous intrafamilial association stud-
ies and limited chromosomal marker analyses have shown
linkage to the MHC (IDDM1) on chromosome 6, and the
insulin locus (IDDM2) on chromosome 11. Two recent stud-
ies using dense microsatellite maps (;300 markers at an
average spacing of ;11 centimorgans), reconfirmed the ma-
jor importance of IDDM1, but provided limited, if any, sup-
port for IDDM2. Both studies also identified new suscep-
tability loci (Table 2).
TABLE 2. Susceptibility loci and candidate genes for IDDM
Chromosomal location Locus designation Candidate genes Remarks
NOD mouse
1 Idd-5 Bcg/Lch/Lty (Nramp) Linked to Orch-5
3 Idd-3 IL-2





11 Idd-4 Nosi Linked to Orch-3
14 Idd-8











Abbreviations: Bphs, Bordetella pertussis-induced histamine sensitization; Csfm, colony stimulating factor, macrophage; GAD1, glutamic
acid decarboxylase 1; GAD2, glutamic acid decarboxylase 2; INS, insulin; Nosi, nitric oxide synthase; Nramp, natural resistance-associated
macrophage protein; SOD2, superoxide dismutase 2. [Derived from Ref. 174.]
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VI. POF in Association with Adrenal Autoimmunity
and/or Addison’s Disease
One of the first signs that autoimmunity could be respon-
sible for a failure of ovarian function came from the obser-
vation that ovarian failure could precede the onset of Ad-
dison’s disease by 8–14 yr (177).
Addison’s disease is an uncommon disorder (10–20 per
million) caused by a deficiency of adrenocortical hormones.
The prevalence is highest in the fourth decade of life, and
there is a marked female preponderance (2.5:1). The nature
of idiopathic Addison’s disease in the majority of patients in
developed countries is now regarded as autoimmune (178),
in contrast to the nature of the disease in developing coun-
tries, which is still mainly due to tuberculosis (179). Auto-
immune Addison’s disease seldom develops in isolation, and
several other endocrine glands and organs are generally af-
fected (180), leading to an autoimmune polyglandular syn-
drome (APGS). Two main forms of APGS can be clinically
discerned. APGS type I mainly affects children and is char-
acterized by the association of mucocutaneous candidiasis,
hypoparathyroidism, and Addison’s disease. Ovarian failure
is often part of the syndrome (in approximately 60% of cases).
APGS type 1 is also termed APECED (autoimmune polyen-
docrinopathy-candidosis-ectodermal dystrophy). APGS
type II is characterized by adrenal failure in association with
hypothyroidism. The latter mainly occurs in the fourth de-
cade of life and has a female preponderance. In this syn-
drome only 25% of women have amenorrhea and 10% have
a classic POF (181, 182).
With regard to POF, the literature indicates that 2–10% is
associated with Addison’s disease and/or adrenal autoim-
munity (183).
A. Antibodies in POF patients with adrenal autoimmunity
and/or Addison’s disease
The discovery in the 1970s of autoantibodies to the adrenal
cortex (adrenal cytoplasmatic antibodies, Cy-Ad-Abs)
formed an important impetus for the studies on the auto-
immune nature of idiopathic Addison’s disease. Two vari-
eties of adrenal antibodies were subsequently recognized in
the sera of patients with Addison’s disease using indirect
immunofluorescence (IIF) and cryostat sections of human or
monkey adrenal glands. One variety demonstrated reactivity
with the three layers of the adrenal cortex only, whereas the
other variety also reacted with cytoplasmic antigens of other
steroid-producing cells present in the ovary, testis, and pla-
centa (184, 185). This latter subvariety of adrenal cytoplasmic
antibodies was called steroid-cell antibodies (St-C-Abs), and
its reactivity could be absorbed by adrenal homogenates,
thus confirming the cross-reactivity with the adrenal cyto-
plasmic antibodies (186). There is an absolute association
between the presence of St-C-Ab and that of Cy-Ad-Ab, the
former being detectable only when the latter is also present.
St-C-Ab are of the IgG type and bind within the ovary to the
hilar cells, the cells of a developing follicle, such as theca and
granulosa cells, and to the corpus luteum cells.
Almost all patients with a primary amenorrhea and Ad-
dison’s disease have a detectable serum titer of St-C-Ab; 60%
of patients with a secondary amenorrhea and Addison’s
disease show these antibodies (Table 3). In the absence of
clinically overt gonadal failure, St-C-Ab have been described
in about 15–20% of patients with clinical or latent Addison’s
disease (181). In the follow-up of the St-C-Ab-positive add-
isonian patients, about 40% of females developed ovarian
failure in a period of 10–15 yr, whereas in males the St-C-Abs
did not herald gonadal failure (however, numbers of studied
patients were small).
Heterogeneity exists between type I and type II APGS in
relation to St-C-Ab (Table 3): 60–80% of patients with hy-
poparathyroidism and Addison’s disease (type I APGS) and
25–40% of patients with type II APGS show these antibodies.
In type 1 APGS without Addison’s disease, 10% of patients
show St-C-Abs. The high prevalence of St-C-Ab in patients
with APGS type I probably explains the common association
with gonadal failure seen in this group, and the appearance
of the St-C-Abs in a female patient with APGS type I without
adrenocortical or ovarian failure signals a high risk of their
development (185, 187, 188). The sensitivities/specificities/
predictive values for St-C-Abs in females with type 1 APGS
who initially had normal adrenocortical and ovarian func-
tion were 1.0/0.56/0.50 in predicting ovarian failure and
0.86/0.83/0.86 for St-C-Abs in predicting adrenocortical fail-
ure (188).
The mere presence of an autoantibody in the serum of a
patient is certainly not evidence for the pathogenic signifi-
cance of the antibody; the autoantibody may also be the
consequence of cellular destruction, such as is seen after the
destruction of cardiac muscle cells in myocardial infarction,
giving rise to anti-heart cell antibodies. It has been shown,
however,that sera of patients with APGS type I and Addi-
son’s disease, positive for Cy-Ad-Ab and St-C-Ab, are
cytotoxic for cultured granulosa cells in the presence of com-
plement, when high titers of these antibodies were demon-
strated in nine of 23 cases (189). Complement-dependent
cytotoxicity of the St-C-Abs might indeed be one of the mech-
anisms leading to destruction of steroid-producing cells in
vivo and thus to ovarian failure.
In recent years, considerable progress has been made with
regard to the identification of the target antigens of Cy-Ad-
Abs and possibly of St-C-Abs (190). It has been found that the
adrenal cytochrome p450 enzyme 21 hydroxylase (which
converts 17-a-progesterone and progesterone into 11-deoxy-




With autoimmune thyroid disease or, type 1 diabetes 5–10%
With Addison’s disease - primary amenorrhea 100%
- secondary amenorrhea 60%
Addison’s disease (without ovarian failure)
Isolated cases 10–20%
With hypoparathyroidism/candidiasis (type I APGS) 60–80%
With autoimmune thyroid disease (type II APGS) 25–40%
Type I APGS, mucocutaneous candidiasis and
hypoparathyroidism without Addison’s disease
10%
Autoimmune thyroid disease or type 1 diabetes ,1%
Healthy controls ,1%
[Derived from Refs. 181, 186, 188, and own data.]
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cortisol and deoxycorticosterone), is the major autoantigen
recognized by autoantibodies present in patients with Ad-
dison’s disease (191, 192), either in the form of isolated ad-
renal failure or associated with hypothyroidism (type II
APGS).
In type I APGS it is thought that autoantibodies are di-
rected to other members of the cytochrome p450 enzyme
family, namely to the p450 side-chain cleavage enzyme
(p450-scc) and to 17-a-hydroxylase (17-a-OH) (192–196), and
to an ill-defined 51-kDa protein (197). However, there is some
confusion on this subject, and not all investigators could
confirm the presence of these autoantibodies in type 1 APGS
[negative results: p450-scc (198); 17-a-OH (198, 199)]. Of the
steroidogenic p450 enzymes 21-hydroxylase is adrenal-spe-
cific, 17-a-OH is expressed in both adrenals and gonads,
whereas p450-scc is present in adrenal, gonads, and placenta.
The 51-kDa protein is present in islets, granulosa cells, and
placenta.
Possible targets of the St-C-Abs in POF patients not be-
longing to the groups of APGS I or II are thus 17-a-OH and
the p450-scc enzyme. However, in the one such patient with
St-C-Abs, 17-a-OH was not recognized (191). To the authors’
knowledge, studies have not been published on correlations
between the presence and activity of St-C-Abs and autoan-
tibodies to either 17-a-OH or p450-scc in patients without
APGS type 1. Also, studies in which St-C-Ab activity would
be adsorbed with the enzymes 17-a-OH or p450-scc would
further illuminate the subject.
Apart from the autoantibodies, another strong argument
for considering St-C-Ab-positive ovarian failure as an auto-
immune disease is the histology of the ovarian lesions.
B. Histology of the ovaries in patients with POF in
combination with adrenal autoimmunity and/or Addison’s
disease
Table 4 gives an overview of the reported histology of POF,
including the reported cases of histologically confirmed oo¨-
TABLE 4. Histology of ovaries in relation to the antibody profile (adrenal/steroid cell antibody positive or negative) of the POF patients
Reference Year Cases Antibodies Other antibodies/diseases Histology of cases






A. With adrenal/steroid cell antibodies
Irvine et al. (185) 1968 1 1 1 Testis 1
Irvine (293) 1980 5 1 1 Addison’s disease 53 1
Coulam et al. (294) 1981 1 1 1 Thyroid abs1, gastric abs1 1
Gloor and Horlimann (202) 1984 1 2 1 2 1
Rabinowe et al. (295) 1986 1 1 1 Addison’s disease 3 yr later 1
Sedmak et al. (201) 1987 1 1 1 Thyroid abs1 1
Anonymous (272) 1987 1 2 1 Thyroid abs1 1
Wolfe and Stirling (296) 1988 1 1 1 Testis abs1 1
Biscotti et al. (297) 1989 1 1 1 Testis abs1, gastric abs1 1
Bannatyne et al. (200) 1990 1 2 1 Thyroid abs1, Hashimoto’s disease 1
1 2 1 Gastric abs1, ANA1 1
1 1 1 2 1
Lonsdale (298) 1991 1 1 1 2 1
1 1 1 Thyroid abs1 1
B. Without adrenal/steroid cell antibodies
Russell et al. (299) 1982 1 2 2 Granulomatous oo¨phoritis 1
1 n.a. n.a. n.a. 1
Friedman et al. (300) 1987 1 2 2 Thyroid abs1 1
Bannatyne et al. (200) 1990 1 2 n.a. n.a. 1
1 n.a. n.a. n.a. 1
1 2 2 2 1
Kinch et al. (49) 1965 9 n.a. n.a. n.a. 2 6 1 2
Emperaire et al. (301) 1970 7 n.a. n.a. n.a. 2 5 2 0
Zarate et al. (302) 1970 7 n.a. n.a. n.a. 2 4 3 0
Sharf et al. (303) 1972 10 n.a. n.a. n.a. 2 8 2 0
Starup and Sele (33) 1973 15 n.a. n.a. n.a. 2 7 6 2
Falk (304) 1977 3 n.a. n.a. n.a. 2 2 1 0
Duignan et al. (305) 1978 8 n.a. n.a. n.a. 2 3 3 2
Board et al. (306) 1979 8 2 2 2 2 2 4 2
Rebar et al. (41) 1982 9 n.a. n.a. Thyroiditis 33 2 5 4 n.a.
Russell et al. (299) 1982 19 2 2 2 2 14 0 3
Menon et al. (307) 1984 43 n.a. n.a. n.a. 2 27 16 n.a.
Aiman and Smentek (308) 1985 14 2 2 Crohn’s disease 13, SLE 13, Graves’ 13 2 9 2 5
Miyake et al. (244) 1987 10 2 2 IDDM 13, Thyroiditis 33 2 10 0 0
Rebar and Connolly (309) 1990 12 2 2 n.a. 2 5 7 n.a.
Muechler et al. (219) 1991 17 2 2 ANA1 53, thyroid abs1 23, testis abs1 13 2 12 2 3
Total 215 24 119 53 19
11% 55% 25% 9%
abs, Antibodies; ANA, antinuclear antibody; IDDM, insulin-dependent diabetes mellitus; n.a., data not available; SLE, systemic lupus
erythematosis.
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phoritis. All St-C-Ab-positive cases had lymphocytic oo¨pho-
ritis, and of all lymphocytic oo¨phoritis cases reported, 78%
had St-C-Abs.
The macroscopic appearance of ovaries with lymphocytic
oo¨phoritis was either cystic (50% of the cases), with smaller
and larger cysts, or normal. The cyst formation is hypothe-
sized to be due to the elevated levels of gonadotropins seen
in these patients.
Concerning the pattern of microscopical infiltration, there
is a marked similarity in the reported cases of lymphocytic
oo¨phoritis in the different compartments of the ovary. In
most cases the primordial follicles are unaffected, as well as
the cortex of the ovary. It is the developing follicle that is
predominantly infiltrated by mononuclear inflammatory
cells. There is a clear pattern of increasing density of the
infiltration with more mature follicles. Preantral follicles are
surrounded by small rims of lymphocytes and plasma cells,
whereas larger follicles have a progressively more dense
infiltrate usually in the external and internal theca. The gran-
ulosa layer is usually spared in this process until luteiniza-
tion of the degenerating follicle occurs. When cysts are
present, they are luteinized with a marked leukocytic infil-
tration in the cyst wall and destruction of the lining cells.
Atretic follicles and, when present, corpora lutea or corpora
albicantia are infiltrated as well. This pattern of infiltration
confirms that steroid-producing cells are a main target for the
autoimmune attack. Mild infiltration might be seen in the
medulla and hilar region of the ovaries. There is a perivas-
cular and, surprisingly, a perineural infiltration in the hilus
of the ovary (200).
Immunohistochemical analysis of the lymphocytic oo¨phori-
tis reveals that the inflammatory cells are mainly formed by T
lymphocytes (CD41 and CD81) with a few B cells, together with
large numbers of plasma cells. Macrophages and NK cells can
also be found. The plasma cells mainly secrete IgG, but also IgA
or IgM (201, 202), which probably indicates the local production
of ovarian autoantibodies. That T cells are important in the
ovarian destructive autoimmune reaction is mainly supported
by data generated in the animal models of autoimmune lym-
phocytic oo¨phoritis (see below). The involvement of T cells also
in human oo¨phoritis is suggested by a case report on a patient
with autoimmune thyroiditis, adrenalitis, and POF in whom
migration-inhibiting factor (MIF) production by peripheral T
cells toward ovarian as well as testicular antigens was found
(203). The MIF test is a sensitive antigen-specific test for the
production of a cytokine, MIF, by peripheral blood T-lympho-
cytes when cultured in the presence of specific antigens. It must
also be noted in this respect that granulosa cells of POF patients
are more sensitive to g-IFN, another T cell cytokine, than normal
granulosa cells (55).
C. Immunogenetic aspects of POF in association with
adrenal autoimmunity and/or Addison’s disease
POF in association with adrenal autoimmunity and/or
Addison’s disease has not been analyzed for any separate
immunogenetic susceptibility for the ovarian component.
Autoimmune Addison’s disease itself is associated with the
haplotype HLA-B8/DR3, and in particular with the DR B1*
0301 allele (204).
Ovarian failure in the context of the APGS type I syndrome
has been studied in more detail, and APGS type I does not
display an HLA-B8/DR3 association. The only association of
APGS type I and HLA haplotypes reported so far has been
with HLA-A28 (205). Positive associations were found be-
tween the presence of HLA-A28 and hypoparathyroidism,
adrenocortical failure, and IDDM within the APGS type I
syndrome, but not with ovarian failure (205), which is im-
portant for this review. Interestingly, in the APGS type I
patients with ovarian failure, HLA-A3 was more frequent
while HLA-A9 was less frequent than in those with normal
ovarian function (205). Using the microsatellite approach, the
responsible gene for APGS type I has recently been mapped
to the long arm of chromosome 21 (206). The Unverricht-
Lundborg type of progressive epilepsy EPM1 has been
mapped to the same locus, viz 21q,22.3, and a candidate gene
(EHOC-1) for APGS type I, but in particular for EPM1, has
been identified as a gene coding for a protein with partial
homologies to transmembrane proteins including sodium
channel proteins (207).
D. Conclusions
If the above observations are correct, POF in the presence
of Addison’s disease and/or adrenal autoimmunity (only
2–10% of cases) is almost certainly an endocrine autoimmune
disorder. This view is supported by: 1) the presence of au-
toantibodies to steroid-producing cells in the patients, 2) the
characterization of shared autoantigens between adrenal and
ovarian steroid-producing cells, and 3) the histological pic-
ture of ovaries of such cases (lymphoplasmacellular infiltrate
particularly around steroid-producing cells).
The existence of an animal model for the autoimmune
syndrome of adrenalitis/oo¨phoritis (see below) lends addi-
tional support to this view. It is clear that further genetic
studies need to be performed to analyze whether there is a
separate (immuno)genetic susceptibility for the ovarian com-
ponent within the syndrome oo¨phoritis/adrenalitis.
VII. Signs of Ovarian Autoimmunity in Patients with
Idiopathic POF in the Absence of Adrenal
Autoimmunity and/or Addison’s Disease
A. Histology of the ovaries in patients with idiopathic POF
in the absence of adrenal autoimmunity and/or Addison’s
disease
The histological picture of ovaries of POF patients without
adrenal autoimmune disease is also summarized in Table 4.
Approximately 60% of such cases of POF lack ovarian fol-
licles, and in these cases fibrotic ovaries are found. In 40% of
the cases, ovarian follicles are detectable and numbers vary
from few to numerous. About 10% of such follicular cases
have numerous follicles, and these latter cases probably be-
long to the ROS (208).
In 1969, Jones and de Moraes-Ruehsen (50) were the first
to report on three patients with ROS; they called it the “Sav-
age” syndrome after the name of their first patient. The
syndrome is defined by the presence of numerous primordial
follicles in the ovaries, a hypergonadotropic hypoestrogenic
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hormone profile, and a hyporeceptivity for high dosages of
exogenous gonadotropins given for ovulation induction in
patients with either primary (49, 50) or secondary amenor-
rhea (51, 209–216). ROS patients with a secondary amenor-
rhea clinically present as POF patients. The etiology of the
syndrome is unknown, although several hypotheses have
been put forward. These range from a lack of gonadotropin
or estrogen receptors, postreceptor pathway disturbances,
gonadotropins with inadequate bioactivity (217), serum fac-
tors modulating the action of FSH (218), and immune factors
such as antibodies to gonadotropin receptors and thymus
pathology, which is relevant for this review (216).
It is important to note that cases of lymphocytic oo¨phoritis
can hardly be found in POF patients in the absence of adrenal
autoimmunity/Addison’s disease [six of 215 cases (Table 4)].
Muechler et al. (219), however, showed the presence of im-
munoglobulins in such non-oo¨phoritis-affected ovaries us-
ing direct immunofluorescence: in 50% of his cases he found
vascular wall staining (IgA, IgM, or IgG), and in 30% the
stroma and follicular cells were positive for immunoglobu-
lins. Hypothetically, autoantibodies to the ovary may have
been present in the ovary without reaching detectable levels
in the serum or inducing a local inflammation. It must also
be noted that Muechler’s data have not been confirmed by
others, and in fact the histology of POF in the absence of
adrenal autoimmunity/Addison’s disease is not helpful in
supporting an immune pathogenesis of the disease. This also
applies to the atrophy found in the majority of cases. This
phenomenon may represent the endstage of an autoimmune
process directed against ovarian structures (as is seen in
animal models, see below), but it may also represent a final
depletion of oocytes due to genetic or environmental factors.
More positive evidence of isolated POF representing an
endocrine autoimmune disease is the reported higher than
normal frequency of some other endocrine and neurological
autoimmune diseases in POF patients (Table 5).
B. Autoantibodies in patients with idiopathic POF in the
absence of adrenal autoimmunity and/or Addison’s disease
1. Autoantibodies to endocrine organs (Table 5). Thyroid auto-
immunity is the most prevalent (14%) associated endocrine








Behrman (310) 1964 16 0 0 1 0
Lundberg and Persson (291) 1969 1 0 0 0 1
Vallotton and Forbes (311) 1969 2 0 2 0 0
de Moraes-Ruehsen et al. (221) 1972 16 6 4 0 0 Idiopathic thrombocytopenic purpura 13
Ayala et al. (312) 1979 2 2 0 0 0 Sicca syndrome 23
Board et al. (306) 1979 7 0 0 0 1
Collen et al. (313) 1979 1 0 0 0 0 Vitiligo 13, rheumatoid arthritis 13
Williamson et al. (314) 1980 2 1 0 0 2
Coulam and Lufkin (315) 1981 1 0 0 1 0 Anti-ovarian abs (RIA) 13
Kuki et al. (212) 1981 1 0 0 0 1
Chiauzzi et al. (233) 1982 2 0 0 0 2 FSH-receptor abs 23
Russell et al. (299) 1982 19 1 0 0 0 23 oo¨phoritis (Table 4)
Rebar et al. (41) 1982 26 3 0 0 0
Bateman et al. (292) 1983 1 0 0 0 1
Coulam and Ryan (227) 1985 71 5 0 0 1
Tang and Faiman (234) 1983 9 1 0 0 0 Rheumatoid arthritis 13, vitiligo 13,
Hashimoto 13
Aiman and Smentek (308) 1985 32 3 0 1 0 Crohn’s disease 13, SLE 13
Alper and Garner (34) 1985 32 11 0 0 0 Vitiligo 13
Anonymous (271) 1986 1 0 0 0 0 SLE 13
Pekonen et al. (224) 1986 10 0 0 0 0 SLE 13
Friedman (300) 1987 1 1 0 0 0 13 oo¨phoritis (Table 4)
Miyake et al. (244) 1987 20 7 6 0 1 ANA1 83, thyroiditis 13
Ho et al. (245) 1988 44 2 0 0 0 ANA1 13, Rheuma factor1 13
Mignot et al. (316) 1989 21 4 4 4 0 ANA1 103, nDNA1 63,
Rheuma factor1 93, SM1 83
Wolffenbuttel et al. (317) 1987 1 1 0 0 0
Rebar and Connolly (309) 1990 115 12 0 0 0
Luborsky et al. (229) 1990 43 5 n.a. 1 n.a. Rheumatoid arthritis 13, SLE 13
van Weissenbruch et al. (235) 1991 22 2 1 1 1 Anti-pituitary abs1 13, ANA1 13, SM 23
Muechler et al. (219) 1991 12 2 0 0 0 ANA1 53, testis ab1 13
Belvisi et al. (318) 1993 44 9 1 1 0 ANA1 43, SM1 43
Nelson et al. (247) 1992 23 5 4 0 0 Rheumatoid arthritis 13, ANA1 93
Tsirigotis and Craft (216) 1994 1 n.a. n.a. n.a. 1
Hoek et al. (248) 1995 30 3 1 1 2 ANA1 23, SM1 83
Total 629 86 23 11 14
13.8% 3.7% 1.7% 2.2%
abs, Antibodies; ANA, antinuclear antibodies; ACH-R-abs, acetylcholine receptor antibodies; ICA, islet cell antibodies; IDDM, insulin-
dependent diabetes mellitus; MG, myasthenia gravis; n.a., data not available; SLE, systemic lupus erythematosus; SM, smooth muscle. [Derived
from Ref. 183.]
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autoimmune abnormality reported in POF patients without
an adrenal autoimmune involvement, followed by the pres-
ence of parietal cell antibodies (4%), IDDM (2%), and my-
asthenia gravis or positivity for acetylcholine receptor anti-
bodies (2%) (Table 5). However, the general prevalence of
positivity for thyroid antibodies and gastric parietal cell an-
tibodies is only slightly above the prevalence found in nor-
mal populations. It is, however, remarkable that IDDM and
myasthenia gravis, both relatively uncommon autoimmune
diseases (,,1%) are found relatively frequently in POF pa-
tients (2–4%). Whether this high frequency is due to publi-
cation bias or to shared underlying immune dysregulating
factors remains to be established. Systemic lupus erythem-
atosus (SLE), antinuclear antibodies, and rheumatoid factors
have also been reported with a higher frequency than normal
in POF patients (Table 5). A relationship of POF with SLE is
further strengthened by the finding of the presence of anti-
ovarian antibodies in 84% of the cases of female SLE patients
by Moncayo-Naveda et al. (220).
2. Ovarian autoantibodies. Strong support for an autoimmune
character of isolated POF would be the presence of antibodies
to ovarian structures in the serum of these patients. How-
ever, the major conclusion drawn from several investigations
using IIF on gonadal tissue (animal or human) is that patients
are negative for St-C-Abs (186–188, 221–225). It is worthwile
to note that positive results regarding anti-ovarian antibod-
ies have been obtained using assay methods other than rou-
tine IIF (see Table 6), but control subjects without idiopathic
ovarian failure, postmenopausal women, and patients with
iatrogenic ovarian failure were also found positive in these
assays. It has become gradually clear from these studies that
the presence and clinical activity of POF does not correlate
with the presence of these antibodies in serum. Moreover, the
results indicate that although antibodies to ovarian antigens
are common in POF, their pathogenic role remains question-
able. They may be the consequence rather than the cause of
the disease.
3. Receptor autoantibodies. Conflicting results have also been
obtained in investigations on so-called “receptor antibodies.”
Receptor antibodies are directed to membrane receptors for
hormones, and these antibodies can mimic the action of the
hormone if they have a similar specificity and affinity for the
receptor. Stimulating antibodies to the TSH receptor are the
cause of the hyperthyroidism and goiter formation in pa-
tients with Graves’ disease (230). On the other hand, receptor
antibodies may also block the action of the corresponding
hormone when they lack a stimulatory action but still bind
to the receptor. Blocking receptor antibodies have been de-
scribed as causal for myasthenia gravis (blocking antibodies
to the acetylcholine receptor), some forms of insulin-resistant
diabetes (blocking antibodies to the insulin receptor), and
primary hypothyroidism [blocking antibodies to the TSH
receptor (231)].
Thus, it is easily understood that receptors such as the LH
and FSH receptors might become targets for blocking anti-
bodies (Fig. 8), and such hypothetical antibodies could be a
cause of ovarian failure. Experiments showing an interaction
of antibodies of POF patients with FSH and LH receptor
(function) have been described by various authors (Table 7).
However, inconsistent data were generated with regard to
the prevalence and the exact target of these antibodies; more-
over, receptor antibodies were also found in patients with
iatrogenic ovarian failure.
Recent data using cloned human LH and FSH receptors
indicate that the human gonadotropin receptors are highly
selective for their human ligands (240, 241), and this selec-
tivity may also apply for the receptor antibodies. Therefore,
Anasti et al. (237) used recombinant human gonadotropin
receptors to detect a putative presence of immunoglobulins
directed against the gonadotropins or their receptors in sera
of patients with POF. The authors were unable to demon-
strate the presence of blocking antibodies to LH or FSH
receptors in any of the 38 POF patients studied.
In conclusion, the data on receptor antibodies in POF are
not conclusive; antibodies to the LH and FSH receptors may
exist, but their precise role and prevalence require further
studies.
4. Antibodies to zona pellucida (ZP). Yet another specific set of
ovarian antibodies playing a role in POF might be the anti-
bodies to the ZP. The ZP is the acellular matrix that sur-
rounds developing and ovulated oocytes and is also detect-
able in atretic follicles. Autoantibodies to ZP have been
described as a cause of infertility in women. In women with
unexplained infertility, these antibodies were seen in 5.6% of
the cases, whereas in the normal controls positivity was seen
in only 1.7% (242). ZP antibodies were thought to interfere
with the sperm-oocyte interaction, thus inducing infertility.
Animal models have demonstrated, however, that the ZP
antibodies interfere with follicular development, and the
presence of these antibodies in the experimental animals
leads to follicular depletion and amenorrhea (see below).
Grootenhuis et al. (unpublished observations), using an en-
zyme-linked immunosorbent assay, recently found three of
34 POF patients positive for IgG antibodies toward human
recombinant ZP3. However, three of six postmenopausal
TABLE 6. Ovarian antibodies in patients with idiopathic POF
Reference Year Assay system Substrate POF Controls Other diseases
Coulam and Ryan (226) 1979 RIA Human ovary homogenate 14/15 1/10 n.a.
3 /12 p.m.
Coulam and Ryan (227) 1985 RIA Human ovary homogenate 30/110 n.a. n.a.
Damewood et al. (228) 1986 IIF Human ovarian sections 14/27 0/24 5/17 other AID
1 /22 p.m.
Cameron et al. (30) 1988 IIF Monkey ovarian sections n.a. 1/13 4 /10 IOF
Luborsky et al. (229) 1990 ELISA Human ovary/oocytes 25/36 0/20 7/9 POF after pelvic surgery
IIF, Indirect immunofluorescence; ELISA, enzyme-linked immunosorbent assay; AID, autoimmune disease; p.m., postmenopausal women;
n.a., not available; IOF, imminent ovarian failure.
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women were also positive, and it is thus likely that the
antibodies toward ZP3 are the result of ovarian follicle dam-
age, rather than their cause (in analogy to the other antio-
varian antibodies described earlier).
C. Cellular immune abnormalities in patients with
idiopathic POF in the absence of adrenal autoimmunity
and/or Addison’s disease
Recent literature (243) in the field of thyroid autoimmunity
and IDDM indicates that immune cells, such as CD41 Th1
lymphocytes, macrophages, and CD81 T cytotoxic cells, are
more important in the destruction of endocrine cells in en-
docrine autoimmunity as compared with the autoantibodies.
So what is the evidence of such immune cell involvement in
POF in the absence of adrenal autoimmunity and/or Addi-
son’s disease?
Table 8 gives an overview of studies on the numerical
presence of various lymphocyte subsets present in the pe-
ripheral blood of patients with idiopathic POF. Although the
data on the numbers of CD31, CD41, and CD81 T cells vary
between the reported studies, a consistent pattern of an in-
creased number of activated T cells (as defined by MHC-class
II1 or IL-2R1) is evident in the majority of the studies. Similar
increased numbers of activated peripheral blood T cells have
been described in other autoimmune endocrinopathies, such
as recent onset Graves’ disease (249), IDDM (250), and Ad-
dison’s disease (251). A word of caution is needed, however,
because we recently observed that postmenopausal women
may also show raised numbers of activated peripheral T cells
(248). Estrogen substitution lowered the number of activated
peripheral T cells in women with POF, although not to com-
pletely normal levels. Ho et al. (252) also demonstrated the
importance of the estrogen status for the number of periph-
eral blood lymphocyte subsets. We therefore consider the
hypergonadotropic hypoestrogenic hormone status present
in POF patients and postmenopausal women as partly re-
sponsible for the raised numbers of activated blood T cells.
Another more direct indication of the involvement of the T
cell system in the pathogenesis of POF is given in the ex-
FIG. 8. An idiotype-antiidiotype cascade driven by a TSH or FSH
molecule. As can be seen the second anti-idiotypic antibody group in
the cascade is an antibody group that may contain antibodies reacting
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periments of Pekonen et al. (224). They detected in several
cases of POF a positive MIF test toward gonadal antigens.
Taken together, the data on T cells in the literature may
thus provide some support of the existence of a T cellular
autoimmune response toward gonadal antigens in POF.
However, again the question of consequence or cause must
be addressed.
With regard to the peripheral B cell numbers, two of three
studies reported an increase in the number of peripheral
blood B cells (245, 248). One (245) correlated the raised num-
bers of B cells to the presence of various auto-antibodies; we
were unable to confirm this correlation (248). A similar in-
crease in the number of peripheral B cells has been observed
in other autoimmune endocrinopathies. It is therefore not
unreasonable to interpret the raised numbers of peripheral
blood B cells as a sign of activation of the humoral immune
system crucial for autoantibody production, especially be-
cause estrogen substitution in POF women did not lower the
raised number of peripheral B cells (248).
With regard to the number and activity of peripheral NK
cells in POF, two reports have been published. We showed
a decrease in the number of peripheral CD561/CD161/
CD32 NK cells (248). Pekonen (224) showed decreased ac-
tivity (lysis of K562 cells) of normal numbers of peripheral
blood NK cells in 30% of POF women. A lowered activity of
NK cells has also been described in patients with Graves’
disease (253). Because NK cells play a role in immunoregu-
lation, it has been hypothesized that these lowered numbers
of NK cells or the lowered activity of the cells might influence
B and T cells, resulting in the production of autoantibodies.
On the other hand, it has been hypothesized that a decreased
activity of the peripheral blood NK cells indicates a suscep-
tibility for viral infection, thus increasing the chance for a
viral oo¨phoritis. However, there is little clinical or his-
topathological evidence for a viral infection in POF.
An interesting new avenue is the study on the number and
functions of monocytes and monocyte-derived DCs in en-
docrine autoimmune disease. In IDDM (254) and Graves’
disease (255), an abnormal function of monocytes and mono-
cyte-derived DCs (abnormal polarization, abnormal interac-
tion with T cells) has been found by our group. Recently,
studies were extended to POF, and similar disturbances were
found that were not correctable by estrogen substitution
(256).
The abnormalities in the function of peripheral monocytes,
monocyte-derived DCs, T cells, and B cells in patients with
POF seem to be part of a more complex cell-mediated im-
mune abnormality, including defects in the delayed type
hypersensitivity (DTH) reactivity to Candida antigen (256)
and the MIF production of peripheral T cells toward this
commensal antigen (246). Although we do not understand
the clinical significance of these general defects and abnor-
malities in cell-mediated immunity in POF patients (patients
did not show recurrent infections), they might be related to
an immunodysregulation leading to endocrine autoimmu-
nity. It must be noted in this respect that patients with chronic
mucocutaneous candidiasis (part of the APGS type I) and
patients with recurrent vaginal candidiasis (who do show
DTH abnormalities to Candida) also show a raised incidence
of autoantibodies toward ovarian antigens (257). Whether
the APGS type 1 syndrome (where there is a connection
between candidiasis and oo¨phoritis) represents the extreme
of a spectrum of disorders combining T cellular deficiencies
with ovarian autoimmunity requires further investigation.
D. Conclusions
In conclusion, there is some, albeit debatable, evidence that
some cases of idiopathic POF in the absence of Addison’s
disease/adrenal autoimmunity may belong to the group of
endocrine autoimmune diseases.
The positive evidence is formed by the fact that these cases
of POF show similar cellular immune abnormalities to other
endocrine autoimmune diseases such as IDDM, Graves’ dis-
ease, and Addison’s disease. These cellular immune abnor-
malities include abnormalities in the numbers and/or func-
tion of peripheral monocytes, monocyte-derived DC, and
subsets of T cells and B cells. Another point of positive
evidence might be the more than normal association of POF
with IDDM and myasthenia gravis. However, data need to
be confirmed and their relevance investigated. Moreover,
data on anti-ovarian antibodies and anti-receptor antibodies
are not conclusive, because these antibodies, although found
by the majority of authors, might be the consequence rather
than the cause of the disease. Another point of doubt is that
the histology of POF in the absence of Addison’s disease/
adrenal autoimmunity hardly shows oo¨phoritis (,3%).
With regard to immunogenetic studies, one report (258)
gives support for a concept that POF belongs to the endocrine
autoimmune disorders: POF was associated with HLA-DR3
(258). This study, however, involved only 22 POF patients
without adrenal autoimmunity. It must be noted that others
were unable to confirm the association in later studies, using
larger groups of POF patients of whom only a neglectable
number had associated Addison’s disease (259, 260).
VIII. Animal Models of Autoimmune Oo¨phoritis
Animal models can be helpful in elucidating the question:
“Which form of POF is autoimmune in character?” Various
models have been developed, and ovarian failure due to
autoimmune destruction of the ovaries can be induced in
animals using the following approaches:
A. Immunization with crude ovarian antigens.
B. Immunization with well defined ovarian antigens, such
as ZP3, or peptides thereof.
C. Neonatal thymectomy in certain strains of mice.
D. Transfer of normal T cells into syngeneic athymic nude
(nu/nu) mice.
These four approaches will be described in detail in this
review. Other approaches (variants of C. and D.) are the
neonatal treatment of mice with cyclosporin A (261), en-
grafting of fetal rat thymic grafts to nu/nu mice (262), trans-
plantation of neonatal thymic grafts to nu/nu mice (263), and
transfer of normal neonatal spleen cells, neonatal thymo-
cytes, and adult thymocytes to syngeneic nu/nu recipients
(264).
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A. Immunization with crude ovarian antigens
Experimental autoimmune oo¨phoritis can be induced in
animals, such as the rat and the BALB/c mouse, using im-
munization with bovine or rat ovarian extracts in complete
Freund’s adjuvant (265–267). The immunization establishes
an autoimmune allergic oo¨phoritis as early as day 14 after
immunization, with infiltration of the ovaries by immune
cells. The autoimmune nature of the oo¨phoritis is underlined
by a positive DTH reaction toward the injected ovarian an-
tigens by day 14, illustrating the existence of a cell-mediated
immune reaction toward the ovarian antigens. The appear-
ance of germinal centers in the thymus and increased T cell
activity and B cell stimulation in the spleen indicates that this
experimental oo¨phoritis involves both T and B cells (267).
The experimental autoimmune oo¨phoritis could also be in-
duced by passive transfer of peripheral blood lymphocytes,
spleen cells, and enriched T and B cell suspensions from
ovarian antigen-immunized rats to naive recipients, indicat-
ing that T cells and B cells are important in the pathogenesis
of the disease.
Anti-ovarian antibodies in the serum of the affected ani-
mals were not detectable before day 28 (265). The reproduc-
tive capacity of the rats, measured by litter size, could be
correlated to the titer of the anti-ovarian antibodies. More-
over, passive immunization of rats with rabbit anti-rat ovar-
ian serum resulted in a temporary dose-dependent reduction
in litter size (268), indicating a role of the antibodies in the
pathogenesis of the disorder. The antibodies produced in this
experimental oo¨phoritis animal model are thought to inter-
fere with ZP antigens inhibiting fertilization, and/or to dis-
turb ovulation (269).
Histological examination of the ovarian tissue at day 14
after immunization showed characteristic perivenous accu-
mulations of lymphocytes and macrophages as well as
plasma cells (265, 266). The infiltrate was found beneath the
tunica albuginea and in the interfollicular tissue, as well as
in the granulosa layer of follicles. Occasionally, cell infiltrates
were found in the external theca. The large secondary folli-
cles and corpora lutea seemed unaffected, in contrast to the
primordial and small secondary follicles. While the number
of follicles and corpora lutea were decreased, the number of
atretic follicles was increased. It is evident, in comparing the
histology of this experimental oo¨phoritis rat model to the
known cases of human autoimmune oo¨phoritis, that there
are major differences. In human autoimmune oo¨phoritis, the
main targets are the steroid-producing cells of the theca of
maturing follicles and the corpus luteum, and not the inter-
follicular space and the secondary and primordial follicles
such as seen in this animal model. This implies that the model
may have only limited value in the study of human auto-
immune oo¨phoritis and POF.
B. Immunization with heterologous ZP antigens or purified
ZP3 antigens
Immunization of New Zealand white rabbits with heter-
ologous ZP antigens shows an induction of ovarian failure
due to follicle depletion. Immunization experiments with
porcine ZP in rabbits showed the development of ZP anti-
bodies in the immunized animals. It was demonstrated that
rabbits actively immunized with ZP proteins ceased to ovu-
late in response to hCG administration (269). The immuni-
zation of the rabbits induced a marked reduction in follicles
and an atretic appearance of primary follicles. Growing fol-
licles disappeared completely by 30 weeks post immuniza-
tion. The reduction in number of normal follicles was ac-
companied by a striking increase in the number of oocyte-
free cell clusters. An oo¨phoritis such as that seen in the
immunization experiments with crude ovarian extracts was
not detected (270).
The alteration in ovarian function and histology in the
rabbits could be correlated with the presence of serum an-
tibodies to ZP glycoproteins. These studies and the histo-
logical pictures indicate first that the antibodies to ZP alter
ovarian function and histology by interfering with cells dur-
ing the stage of follicle differentiation at which ZP proteins
are being synthesized (270), and second that the model might
be of relevance in the study of human POF in the absence of
adrenal autoimmunity. It has been hypothesized that ROS or
premature depletion of ovarian follicles might represent the
human counterpart of this animal model. However, Starup
and Sele (33) showed that in the ovaries of ROS patients there
was a normal ultrastructural appearance of the early follicles
and no “oocyt-empty” follicle remnants, such as described by
Skinner et al. (270) in the rabbit model. On the other hand, two
cases of ROS have been reported in whom hyalinization of
preantral follicles was described (271, 272).
The proteins of the ZP are conserved among mammals
TABLE 8. Peripheral blood lymphocyte subsets in patients with idiopathic POF
Reference Year Total POFcases
POF 1




T-cells B-cells NK-cells Other
Pekonen et al. (224) 1986 18 2 n.a. n.a. n.a. n.a. n.a. n.a. N NK cell activity ,
MIF production
ovarian antigen .
Miyake et al. (244) 1987 19 0 N N N . . n.a. n.a. Leu-121 B cells .
Ho et al. (245) 1988 45 1 . . .. , n.a. . n.a.
Rabinowe et al. (223) 1989 23 2 N N N N . n.a. n.a. CD51 T cells .
Mignot et al. (246) 1989 23 3 N . N . n.a. N n.a. MIF response
microbial antigens ,
Nelson et al. (247) 1992 24 1 n.a. n.a. n.a. n.a. . n.a. n.a. IL-2 receptor1
T cells .
Hoek et al. (248) 1995 30 0 N N N N . . , DTH candida ,
abs, Autoantibodies; DTH, delayed hypersensitivity skin test; MIF, migration inhibiting factor; N, normal; n.a., data not available; NK,
natural killer; ., increased; ,, decreased.
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(273). ZP3 is a major ZP glycoprotein that functions as a
sperm receptor (274), and mouse and human ZP3 proteins
are 67% identical. It has been shown that a 15-amino-acid
peptide of ZP3 was able to induce oo¨phoritis in (C57BL/
63A/J)F1(B6AF1) mice after immunization in Freund’s com-
plete or incomplete adjuvant. The histology of the lesion was
reminiscent of the picture of human oo¨phoritis. ZP3-specific
T cell responses and antibodies directed to ZP3 were detect-
able in these ZP3-immunized animals (273). In an adoptive
transfer experiment to naive mice, ZP3-specific CD41 T cells
were sufficient for induction of the oo¨phoritis without ob-
servable antibody production to the ZP. The ZP3-specific
CD41 T cells mainly produced IL-2, IFN-g, and TNF, but not
IL-4, indicating that the disease-specific T cells belonged to
the TH1 subset of CD41 T cells.
Subsequently, Lou and Tung (275) very elegantly showed
that a transfer of T cells that were directed to the small T cell
epitope of ZP3 (15-amino acid peptide) alone differed from
the adoptive transfer of T cells to whole ZP3. The former
transfer could already result in a full-blown autoimmune
oo¨phoritis, and, apart from a T cell response to the self-
peptide and histomorphologically confirmed oo¨phoritis, se-
rum antibodies to native ZP3 and preferential binding of the
antibody to the ZP in vivo were found. Crucial in the exper-
iments was the presence of the ovaries during the antigen-
specific CD41 T cell transfer. The phenomenon shows that B
cells autoreactive to ovarian antigens can be generated after
a T cell transfer, and that these cells can be activated by
ZP3-specific CD41 T cells to produce antibodies that are
directed to and bind ZP3 in vivo. It is thought that the ovarian
antigen required for antibody production in this model is
provided by the normal ovaries, since the ZP antigens may
be generated through a process of follicular atresia (epitope
spreading).
Another mechanism by which the ZP autoantibodies can
be induced is by idiotype mimicry of autoantigens in the
absence of the antigen itself. Tung and colleagues (276) also
investigated whether a nonovarian peptide could be recog-
nized by ZP3-specific T cells. The author detected, by search-
ing the protein sequence library, nonovarian peptides shar-
ing sufficient residues with ZP3. Interestingly, the d-chain of
the murine acetylcholine receptor and the ZP3 peptide had
certain homology. The ZP3 peptide derivate and the d-chain
of the acetylcholine receptor both elicited severe oo¨phoritis
and also stimulated the ZP3-specific T cell clone to prolif-
erate. Through the mechanism of T cell peptide mimicry,
using a d-chain of the murine acetylcholine receptor, auto-
immune oo¨phoritis could be elicited by clonal activation of
ZP3-specific pathogenic T cells. Hence, T cell epitope mim-
icry as autoimmune disease mechanism was detected in the
murine model, and this mimicry may explain the clinical
association between POF and myasthenia gravis. Unfortu-
nately, however, in the human there does not exist a homol-
ogy between ZP3 and the acetylcholine receptor (277). Still,
it remains remarkable that there is a marked coincidence
between POF and myasthenia gravis (Table 5). The fact that
in human oo¨phoritis a clear perineural infiltration of the
ovarian hilus nerves is seen might also suggest a shared
pathogenic mechanism between ovarian and neuronal dis-
eases.
C. Neonatal thymectomy models
Neonatal thymectomy in BALB/c mice (and also some
other strains, see below) at day 3 after birth results in oo¨-
phoritis, among other organ-specific autoimmune manifes-
tations such as thyroiditis, gastritis, and parotitis (278–280).
The inflammations are characterized by the presence of T cell
infiltrates in the affected organs and the development of
organ-specific antibodies in the serum. There is a strict tem-
poral relationship between the development of the autoim-
mune syndrome and the day of thymectomy, which has to
occur between the second and the fifth day after birth (280,
281). An explanation for the phenomenon has been proposed
and is based on the premise that self-reactive CD41 T cells
are generated in the thymus throughout life and exported to
the periphery. In euthymic animals, autoimmune disease is
not observed because these autoreactive CD41 T cells are
controlled by CD41 T cells with regulatory or suppressor
activity. These cells are also generated in the thymus, but
only after the first week of life. Hence thymectomy at day 3,
restricting the T cell repertoire to only effector autoimmune
CD41 T cells, explains the spontaneously occurring autoim-
mune diseases, because the balance between self-reactive T
cells and regulatory T cells tips over to the former.
That animal oo¨phoritis is directly due to autoimmune T
cells is shown by transfer experiments of CD41 T cells of
thymectomized donors to young recipients, which causes an
oo¨phoritis in these recipients (282, 283). This transfer of oo¨-
phoritis could be prevented by infusion of CD41 CD51 T
cells from normal adult mice in an early stage after the
transfer of the CD41 cells of the thymectomized donors.
The histopathological events of the oo¨phoritis in the
thymectomized mice occur in an orderly manner. Initially the
oo¨phoritis is evident as a patchy or diffuse infiltration of
lymphocytes; later, developing follicles are clearly affected
and monocytes, macrophages, neutrophils, and plasma cells
are found between and within ovarian follicles. The onset of
puberty markedly potentiates the oo¨phoritis, indicating that
probably a change in antigen profile due to the gonadotropin
stimulation is important. The oo¨phoritis is most severe be-
tween 4–14 weeks after thymectomy. This is accompanied by
loss of ova and collapse of ovarian follicles. Autoantibodies
are detected in the circulation by week 4, with a peak be-
tween weeks 7–9. Autoantibodies are directed toward oo-
cytes, ZP, and in lower titers also to steroid-producing cells
such as the granulosa cells, the theca cells, and the luteal cells.
The inflammation subsides after 14 weeks, and the ovary
becomes atrophic (278–280). IgG-producing plasma cells are
found, but not frequently. The overall picture of the oo¨pho-
ritis is one of a cell-mediated autoimmune reaction.
With regard to the genetics of this ovarian autoimmunity
model, certain strains of mice are susceptible, such as the
BALB/c and A/J mice, whereas other strains (C57bl/6J,
DBA/2 mice) are resistant. Since susceptability and resis-
tance are not associated with the MHC haplotype (H2) of the
mice, these molecules are apparently of minor importance.
Using the susceptible and resistant mice strains and back-
crosses of these strains in combination with a microsatellite
approach, a locus has been found on chromosome 16, con-
trolling the abrogation of the tolerance due to neonatal
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thymectomy day 3 (284). This so-called Aod1 locus was as-
sociated with the presence of oo¨phoritis in the mice. Inter-
estingly, the markers on chromosome 16 failed to exhibit a
significant linkage to the concomitant ovarian atrophy in this
mouse oo¨phoritis model. Rather, this atrophy exhibited an
association with markers on mouse chromosome 3 (284).
With regard to another experimental mouse model of go-
nadal autoimmunity, viz the male counterpart of allergic
oo¨phoritis, experimental allergic orchitis, studies have
shown a similar complexity of gene involvement and the
recognition of various susceptibility and resistance loci (the
Orch genes) (285). In this model the H2 locus is of importance
as a susceptibility locus, and the so-called Orch 1 gene has
been mapped to the Hsp 70.3/G7 interval within the H-2S/
H-2D region. Genes controlling resistance have also been
identified: Orch 3 maps centrally on chromosome 11, while
Orch 4 maps on chromosome 1. Orch 5, also on chromosome
1, is probably a gene governing the extent of the inflamma-
tory lesions seen in susceptable mice. Most significant is the
linkage of Orch 3 to Idd-4 and Orch 5 to Idd-5, two suscep-
tibility genes that play a role in IDDM of the NOD mouse
model (see above and Table 2).
The histological and serological manifestations of the mu-
rine autoimmune oo¨phoritis are comparable to the histolog-
ical and serological picture of human autoimmune oo¨pho-
ritis in association with Addison’s disease. It is remarkable,
however, that the adrenal glands are unaffected in the neo-
natally thymectomized mice, even in the presence of anti-
bodies to steroid-producing cells. However, modifications of
the model, viz immunomodulation using Cyclosporin A af-
ter birth, does affect the adrenals (261).
As the inflammation of the ovaries subsides, serum anti-
oocyte and anti-zona antibodies also decrease to sometimes
undetectable levels at day 150–360, when oocytes have com-
pletely disappeared from the atrophic ovary (278–280).
Therefore, the absence of serum autoantibodies does not
exclude an autoimmune etiology of the ovarian disease. This
finding may be of relevance in patients with adrenalitis
and/or amenorrhea; detection of St-C-Abs may not always
be expected unless they are looked for in an early stage of the
disease.
D. Transfer of normal T cells to athymic (nu/nu) mice
Yet another mechanism for the induction of an autoim-
mune oo¨phoritis is the transfer of T cells to athymic nude
mice.
The nude mouse model is characterized by a deficient T
cell function because the most important function of the
thymus, education of T cells to properly recognize self and
nonself, cannot take place. When CD41CD8-thymocytes
from normal neonatal or adult BALB/c mice are transferred
to athymic mice, approximately 50–75% of the recipients
develop an autoimmune oo¨phoritis and/or gastritis (264).
Neonatal CD41 splenocytes are also able to transfer the au-
toimmune diseases, whereas T cells from adult spleen do not
(286). However, a fraction of adult spleen CD41 with a low
expression of CD51 can induce oo¨phoritis in athymic recip-
ients. The disease-generating CD41 T cells are of the Th1
type. Regulatory T cells that down-regulate self-reactive T
cells in this animal model are also present, as studied by the
combined infusion of neonatal spleen cells that enhance au-
toimmune oo¨phoritis and adult spleen cells that inhibit this
process (264). The exact nature of these regulatory cells in this
animal model is not yet elucidated; however, it is hypothe-
sized that these belong to the Th2 subset of the CD41 T cells.
The ovarian histopathology of day 3 thymectomized an-
imals and nude mice that develop an oo¨phoritis after an
adoptive transfer experiment are indistinguishable; hence it
might be a good model for POF in the presence of adrenal
autoimmunity/Addison’s disease.
In the human situation, experiments of nature show us that
athymic girls show evidence of dysgenetic, atrophic ovaries,
devoid of follicles (287). Whether this is the ultimate conse-
quence of an autoimmune process that began very early on
remains hypothetical.
E. Conclusions
The murine animal oo¨phoritis models of neonatal thymec-
tomy or T cell transfer in the nude animal clearly show that
pathogenic self-reactive T cells exist in the normal neonatal
and adult repertoire of at least the mouse, and that these
autoreactive effector T cells are controlled by regulatory T
cells also existing in the normal adult repertoire. There ev-
idently exists a genetically controlled balance between these
two T cell populations that ensures tolerance to ovarian and
other self-antigens. When the balance tips over in favor of
effector T cell activity, autoimmune oo¨phoritis develops (of-
ten in association with thyroiditis and other endocrine au-
toimmune disorders). This type of murine autoimmune oo¨-
phoritis is histologically and serologically similar to the
human autoimmune oo¨phoritis occurring in association with
adrenal autoimmunity and Addison’s disease (;2-10% of
POF cases). The autoantibodies and the histology of this type
of POF shows that steroid-producing cells are one of the main
targets of the autoimmune response, and autoantigens of
these steroid-producing cells are gradually identified (im-
portant enzymes in steroid synthesis). When all the data are
considered together, POF in association with adrenal auto-
immunity and/or Addison’s disease and positive for St-C-
Abs can now with certainty be considered as an endocrine
autoimmune disease.
The animal models of immunization with crude and pu-
rified ZP antigens demonstrate that autoimmune ovarian
failure can also be reached via other histological pictures and
mechanisms. First, there is the follicular infiltration by var-
ious immune cells in the ZP3-peptide immunization model,
similar to the thymectomy model and the T cell transfer
model in athymic nude mice. This picture is again reminis-
cent of the autoimmune oo¨phoritis seen in POF patients with
St-C-Abs and associated with Addison’s disease. The infil-
tration ultimately leads to follicular depletion and fibrosis.
Second, there is the simple depletion of follicles after im-
munization with crude ZP antigens in the absence of a clear
lymphocytic infiltration, but with the production of antibod-
ies. This model might be most relevant for POF cases without
adrenal involvement and with fibrotic ovaries. Also in the
human, ZP autoantibodies have been detected and there is
some, though weak, evidence that such POF cases belong to
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the group of autoimmune diseases (associations with other
autoimmune diseases, abnormal numbers and functions of
peripheral lymphocytes and monocytes; see earlier discus-
sions in this review). However, further experiments are re-
quired to establish or refute such a view.
IX. Summary
Premature ovarian failure (POF) is defined as a syndrome
characterized by menopause before the age of 40 yr. The
patients suffer from anovulation and hypoestrogenism. Ap-
proximately 1% of women will experience menopause before
the age of 40 yr. POF is a heterogeneous disorder with a
multicausal pathogenesis involving chromosomal, genetic,
enzymatic, infectious, and iatrogenic causes. There remains,
however, a group of POF patients without a known etiology,
the so-called “idiopathic” form. An autoimmune etiology is
hypothesized for the POF cases with a concomitant Addi-
son’s disease and/or oo¨phoritis.
It is concluded in this review that POF in association with
adrenal autoimmunity and/or Addison’s disease (2–10% of
the idiopathic POF patients) is indeed an autoimmune dis-
ease. The following evidence warrants this view: 1) The pres-
ence of autoantibodies to steroid-producing cells in these
patients; 2) The characterization of shared autoantigens be-
tween adrenal and ovarian steroid-producing cells; 3) The
histological picture of the ovaries of such cases (lymphop-
lasmacellular infiltrate around steroid-producing cells); 4)
The existence of various autoimmune animal models for this
syndrome, which underlines the autoimmune nature of the
disease.
There is some circumstantial evidence for an autoimmune
pathogenesis in idiopathic POF patients in the absence of
adrenal autoimmunity or Addison’s disease. Arguments in
support of this are: 1) The presence of cellular immune ab-
normalities in this POF patient group reminiscent of endo-
crine autoimmune diseases such as IDDM, Graves’ disease,
and Addison’s disease; 2) The more than normal association
with IDDM and myasthenia gravis. Data on the presence of
various ovarian autoantibodies and anti-receptor antibodies
in these patients are, however, inconclusive and need further
evaluation.
A strong argument against an autoimmune pathogenesis
of POF in these patients is the nearly absent histological
confirmation (the presence of an oo¨phoritis) in these cases
(,3%). However, in animal models using ZP immunization,
similar follicular depletion and fibrosis (as in the POF
women) can be detected.
Accepting the concept that POF is a heterogenous disorder
in which some of the idiopathic forms are based on an ab-
normal self-recognition by the immune system will lead to
new approaches in the treatment of infertility of these pa-
tients. There are already a few reports on a successful ovu-
lation-inducing treatment of selected POF patients (those
with other autoimmune phenomena) with immunomodu-
lating therapies, such as high dosages of corticosteroids
(288–292).
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